Newsletter | March 25, 2025

03.25.25 -- Challenges In Manufacturing TIL For Clinical Trials

FEATURED EDITORIAL

Challenges In Manufacturing TIL For Clinical Trials

By Liang Li, Resilient Collective

Tumor-infiltrating lymphocyte cell therapy shows promise for treating solid tumors, but its complex manufacturing profile brings a unique set of issues. Gain insight into some things to watch out for.

INDUSTRY INSIGHTS

Developing Injectable Drug Placebo Formulations For Clinical Trials

Article | By Ryan Memmer and William Powers, Singota Solutions

Developing a placebo for an injectable drug requires consideration of the formulation’s impact in trials, chemistry and physical details, ethical concerns, and regulatory compliance.

Time, Logistics, And Manufacturing In Autologous Cell Therapy Clinical Trials

Article | By Karen Ivester, inSeption Group

Learn how the establishment of effective guidelines and standardization relevant to cell therapy development can help to minimize delays and lead to more positive outcomes.

Top 5 Dos And Don'ts Of RTSM

Article | By James Stringer, Signant Health

Discover best practices and common pitfalls for sponsors and vendors in RTSM as well as how to optimize your study by leveraging vendor expertise, avoiding delays, and embracing innovation.

SOLUTIONS

Optimize Your Randomization And Trial Supply Management

Mednet